ECHO-7 (trade name Rigvir) is a wild type member of the echovirus group of viruses. [1] It was formerly approved as a virotherapy medication by the State Agency of Medicines of the Republic of Latvia (2004–19). [2]

ECHO-7 RIGVIR® contains a non-genetically modified, non-pathogenic, non-toxic virus. It belongs to the Picornaviridae family, Enterovirus genus, Enteric Cytopathogenic Human Orphan group, type 7 (ECHO-7) and is adapted to cancer cells.

An oncolytic, nonpathogenic ECHO-7 virus adapted for melanoma that has not been genetically modified (Rigvir) is approved and registered for virotherapy, an active and specific immunotherapy, in Latvia since 2004.

Danatronics™ offers our newest ultrasonic precision thickness gage line, the ECHO 7 series. ECHO 7 represents our most advanced thickness gage ever.

Conclusions: The results suggest that Rigvir® in vitro reduces the viability of cells of human melanoma, rhabdomyosarcoma, gastric adenocarcinoma, lung carcinoma, pancreas adenocarcinoma but not in PBMC. The presence of Rigvir® in the sensitive cells was confirmed using anti-ECHO-7 antibodies.

Jan 31, 2020 · Purpose: To describe a case of choroidal melanoma treated with Rigvir® virotherapy in an adjuvant setting. Observations: A female patient born in 1956 presented with a small choroidal melanoma in October 2007. 34 months after transpupillary thermotherapy the state of her eye worsened until tumor growth was visualized.

Feb 28, 2018 · The presence of Rigvir® in the sensitive cells was confirmed using anti-ECHO-7 antibodies. The present results suggest that a mechanism of action for the clinical benefit of Rigvir® is its cytolytic properties.

Check each product page for other buying options. Recycled Content Certification for Electrical and Electronic Equipment certifies the total percentage of recycled material in covered products.

Echo Dot (5th Gen, 2022 release) | With bigger vibrant sound, helpful routines and Alexa | Glacier White

Jul 26, 2016 · Oncolytic virotherapy is a recent addition to cancer treatment. Here, we describe positive treatment outcomes in three patients using Rigvir virotherapy. One of the patients is diagnosed with melanoma stage IV M1c, one with small cell lung cancer stage IIIA, and one with histiocytic sarcoma stage IV.